{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:15:35Z","timestamp":1780352135453,"version":"3.54.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2019,7,3]]},"DOI":"10.1080\/14737175.2019.1628640","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T05:25:40Z","timestamp":1559798740000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD"],"prefix":"10.1080","volume":"19","author":[{"given":"Fatuma","family":"Nageye","sequence":"first","affiliation":[{"name":"Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK"},{"name":"Center for Innovation in Mental Health, Academic Unit of Psychology, University of Southampton, Southampton, UK"},{"name":"Solent NHS Trust, Southampton, UK"},{"name":"New York University Child Study Center, New York, NY, USA"},{"name":"Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.6.942"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170500471X"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30190-0"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30269-4"},{"key":"CIT0006","unstructured":"Sunovion. A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years old with attention-deficit hyperactivity disorder (ADHD) in a simulated classroom setting. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03231800 NLM Identifier: NCT03231800."},{"key":"CIT0007","unstructured":"Sunovion. A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with attention-deficit hyperactivity disorder (ADHD) in a simulated classroom setting. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02734693 NLM Identifier: NCT02734693."},{"key":"CIT0008","unstructured":"Sunovion. Dasotraline pediatric ADHD study. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02428088 NLM Identifier: NCT02428088."},{"key":"CIT0009","unstructured":"Sunovion. Dasotraline adult ADHD study. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02276209 NLM Identifier: NCT02276209."},{"key":"CIT0010","unstructured":"Supernus Pharmaceuticals, Inc. Treatment of impulsive aggression (IA) in adolescent with ADHD in conjunction with standard ADHD treatment. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03597503 NLM Identifier: NCT03597503."},{"key":"CIT0011","unstructured":"Supernus Pharmaceuticals, Inc. Treatment of impulsive aggression in subjects with ADHD in conjunction with standard ADHD treatment (CHIME 1). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02618408 NLM Identifier: NCT02618408."},{"key":"CIT0012","unstructured":"Supernus Pharmaceuticals, Inc. Treatment of impulsive aggression in subjects with ADHD in conjunction with standard ADHD treatment (CHIME 2). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02618434 NLM Identifier: NCT02618434."},{"key":"CIT0013","unstructured":"Otsuka Pharmaceutical Development & Commercialization, Inc. A trial evaluating the efficacy, safety, & tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03605680 NLM Identifier: NCT03605680."},{"key":"CIT0014","unstructured":"Otsuka Pharmaceutical Development & Commercialization, Inc. A trial to evaluate the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03605836 NLM Identifier: NCT03605836."},{"key":"CIT0015","unstructured":"Neurovance, Inc. Safety and efficacy study of centanafadine sustained-release (CTN SR) in adults with attention-deficit hyperactivity disorder (ADHD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02547428 NLM Identifier: NCT02547428."},{"key":"CIT0016","unstructured":"Otsuka Pharmaceutical Development & Commercialization, Inc. The safety and efficacy of OPC-64005 in the treatment of adult attention-deficit\/hyperactivity disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03324581 NLM Identifier: NCT03324581."},{"key":"CIT0017","unstructured":"Aevi Genomic Medicine. Efficacy and safety of NFC-1 in adolescents wth genetic disorders impacting mGluR and ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02777931 NLM Identifier: NCT02777931."},{"key":"CIT0018","unstructured":"Aevi Genomic Medicine. PART B: efficacy and safety of AEVI-001 in children and adolescents with ADHD and without mGluR mutations. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03609619 NLM Identifier: NCT03609619."},{"key":"CIT0019","unstructured":"Aevi Genomic Medicine. PART A: efficacy and safety of AEVI-001 in children and adolescents with ADHD and with mGluR mutations. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03265119 NLM Identifier: NCT03265119."},{"key":"CIT0020","unstructured":"Alcobra Ltd. Safety and tolerability study of metadoxine extended release (MDX) (previously known as MG01CI) in PI-ADHD adolescent subjects. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02189772 NLM Identifier: NCT02189772."},{"key":"CIT0021","unstructured":"Alcobra Ltd. A 6 week study of MG01CI 1400 mg compared with placebo in adults with ADHD (attention deficit\/hyperactivity). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02059642 NLM Identifier: NCT02059642."},{"key":"CIT0022","unstructured":"NLS-1 Pharma Inc. Mazindol controlled release in adults with attention deficit hyperactivity disorder (ADHD). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808104 NLM Identifier: NCT02808104."},{"key":"CIT0023","unstructured":"Lundbeck H A\/S. Investigating the effect of vortioxetine in adult ADHD patients. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02327013 NLM Identifier: NCT02327013."},{"key":"CIT0024","unstructured":"Chiba University. Tipepidine in children with attention deficit\/hyperactivity disorder (AD\/HD): a double-blind, placebo-controlled trial. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02305134 NLM Identifier: NCT02305134."},{"key":"CIT0025","unstructured":"King\u2019s College London; South London and Maudsley NHS Foundation Trust. Experimental medicine in ADHD \u2013 Cannabinoids (EMA-C). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02249299 NLM Identifier: NCT02249299."},{"key":"CIT0026","unstructured":"Alcobra Ltd. The MEASURE study \u2013 a phase 3 study of MDX 1400 mg daily compared with placebo in adults with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477748 NLM Identifier: NCT02477748."},{"key":"CIT0027","unstructured":"Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER low dose in children with ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247530 NLM Identifier: NCT03247530."},{"key":"CIT0028","unstructured":"Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER high dose in children with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247543 NLM Identifier: NCT03247543."},{"key":"CIT0029","unstructured":"Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER low dose in adolescents with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247517 NLM Identifier: NCT03247517."},{"key":"CIT0030","unstructured":"Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER high dose in adolescents with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247556 NLM Identifier: NCT03247556."},{"key":"CIT0031","unstructured":"Douglas Sears. A study of combination therapy in children with ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01940978 NLM Identifier: NCT01940978."},{"key":"CIT0032","unstructured":"Supernus Pharmaceuticals, Inc. Efficacy and safety of SPN-812 ER in children with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02633527 NLM Identifier: NCT02633527."},{"key":"CIT0033","unstructured":"Massachusetts General Hospital. Oxytocin and cognitive control in Adult ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2019 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03136263"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0083"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719836159"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119832538"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02244-2"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0503-y"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2018-300050"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-012-0132-y"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12036"},{"key":"CIT0051","first-page":"9(383)","author":"Finan C","year":"2017","journal-title":"Sci Transl Med"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30096-3"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2019.1628640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T12:39:10Z","timestamp":1561639150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2019.1628640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,6,12]]},"published-print":{"date-parts":[[2019,7,3]]}},"alternative-id":["10.1080\/14737175.2019.1628640"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2019.1628640","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}